ICON PLC (ICLR) - Total Liabilities

Latest as of September 2025: $7.17 Billion USD

Based on the latest financial reports, ICON PLC (ICLR) has total liabilities worth $7.17 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ICON PLC - Total Liabilities Trend (1998–2024)

This chart illustrates how ICON PLC's total liabilities have evolved over time, based on quarterly financial data. See ICON PLC working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

ICON PLC Competitors by Total Liabilities

The table below lists competitors of ICON PLC ranked by their total liabilities.

Company Country Total Liabilities
Shanghai Putailai New Energy Technology Co.Ltd.
SHG:603659
China CN¥26.89 Billion
RHB Bank Bhd
KLSE:1066
Malaysia RM323.91 Billion
MARKS SPENCER ADR LS-25
F:MA6A
Germany €5.87 Billion
Futu Holdings Ltd
NASDAQ:FUTU
USA $188.10 Billion
Hindustan Petroleum Corporation Limited
NSE:HINDPETRO
India Rs1.37 Trillion
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
Germany €12.83 Billion
FSN E-Commerce Ventures Limited
NSE:NYKAA
India Rs31.09 Billion
Dr. Reddy's Laboratories Limited
F:RDDA
Germany €187.14 Billion

Liability Composition Analysis (1998–2024)

This chart breaks down ICON PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ICON PLC stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.77 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.43 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ICON PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ICON PLC (1998–2024)

The table below shows the annual total liabilities of ICON PLC from 1998 to 2024.

Year Total Liabilities Change
2024-12-31 $7.35 Billion -5.09%
2023-12-31 $7.75 Billion -10.80%
2022-12-31 $8.69 Billion -6.79%
2021-12-31 $9.32 Billion +487.89%
2020-12-31 $1.59 Billion +22.95%
2019-12-31 $1.29 Billion +28.95%
2018-12-31 $999.97 Million +4.64%
2017-12-31 $955.62 Million +8.51%
2016-12-31 $880.67 Million -7.76%
2015-12-31 $954.71 Million +65.29%
2014-12-31 $577.59 Million +8.59%
2013-12-31 $531.88 Million +18.85%
2012-12-31 $447.53 Million +26.45%
2011-12-31 $353.92 Million +26.61%
2010-12-31 $279.54 Million -16.84%
2009-12-31 $336.15 Million -18.20%
2008-12-31 $410.92 Million +35.42%
2007-12-31 $303.43 Million +75.92%
2006-12-31 $172.48 Million +61.78%
2005-12-31 $106.61 Million -10.08%
2004-12-31 $118.56 Million +73.19%
2003-12-31 $68.46 Million -30.22%
2002-12-31 $98.10 Million +88.76%
2001-12-31 $51.97 Million +67.49%
2000-12-31 $31.03 Million +34.53%
1999-12-31 $23.07 Million -1.85%
1998-12-31 $23.50 Million --

About ICON PLC

NASDAQ:ICLR USA Diagnostics & Research
Market Cap
$11.15 Billion
Market Cap Rank
#2386 Global
#864 in USA
Share Price
$146.00
Change (1 day)
+1.91%
52-Week Range
$80.08 - $202.92
All Time High
$346.20
About

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more